This article is a correction to:
Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept
J. I. Meesters-Ensing1†
R. Admiraal1,2*†L. Ebskamp3A. Lacna3J. J. Boelens4C. A. Lindemans1,2S. Nierkens1,3- 1Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- 2Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
- 3Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
- 4Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, United States
A Corrigendum on
Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept
by Meesters-Ensing J, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA and Nierkens S (2022). Front. Pharmacol. 13:828094. doi: 10.3389/fphar.2022.828094
In the published article, there was an error. The unit of AUC used throughout the paper is incorrect.
A correction has been made to the sections “Patients eligible for TDM and simulation for the calculated optimal dose,” (paragraph 3) “Therapeutic drug monitoring” (paragraph 2) and to the footnotes of Table 1. The unit for AUC previously stated:
“AU*day/L”
The corrected unit for AUC appears below:
“AU*day/mL”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: anti-thymocyte globulin (ATG), TDM (therapeutic drug monitoring), stem cell transplant (SCT), antibody, pediatrics-children
Citation: Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA and Nierkens S (2024) Corrigendum: Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept. Front. Pharmacol. 15:1444228. doi: 10.3389/fphar.2024.1444228
Received: 05 June 2024; Accepted: 28 June 2024;
Published: 06 August 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Meesters-Ensing, Admiraal, Ebskamp, Lacna, Boelens, Lindemans and Nierkens. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: R. Admiraal, ci5hZG1pcmFhbC00QHByaW5zZXNtYXhpbWFjZW50cnVtLm5s
†These authors have contributed equally to this work